Therefore, immunotherapy that involves the activation of both CD8α+CD11c+ and CD8α−CD11c+ cDCs by cancer Ags combined with an adjuvant may elicit both CTL and Th immune responses against cancer cells, thereby improving the efficacy of the treatment. The gene discussed is ITGAX; the disease is cancer.